Esperion Therapeutics, INC Form 4 insider transactions

Eric Warren, Chief Commercial Officer of Esperion Therapeutics, sold 2,234 shares of common stock on December 17, 2024, to satisfy tax obligations related to vested restricted stock units.

Esperion Therapeutics CEO Sheldon L. Koenig sold 12,447 shares of common stock on December 17, 2024, to satisfy tax obligations related to vested restricted stock units.

Esperion Therapeutics' Chief Commercial Officer, Eric Warren, sold 197 shares of common stock to cover tax obligations related to vested restricted stock units.

Esperion Therapeutics' Chief Commercial Officer, Eric Warren, sold 107 shares of common stock on October 17, 2024, to satisfy tax obligations related to vested restricted stock units.

Esperion Therapeutics CEO Sheldon L. Koenig sold 14,550 shares of common stock on September 17, 2024, to satisfy tax obligations related to vested restricted stock units.

Esperion Therapeutics' Chief Commercial Officer, Eric Warren, reports the sale of 2,608 shares of common stock to cover tax obligations arising from vested restricted stock units.

Chief Commercial Officer Eric Warren sold 211 shares of Esperion Therapeutics (ESPR) stock on August 19, 2024, to satisfy tax obligations related to vested restricted stock units.

Esperion Therapeutics' Chief Commercial Officer, Eric Warren, sold 108 shares of common stock on July 17, 2024, to satisfy tax obligations related to vested restricted stock units.

Joanne M. Foody, Chief Medical Officer of Esperion Therapeutics, sold 917 shares of common stock on July 17, 2024, to cover tax obligations arising from vested restricted stock units.

Joanne M. Foody, Chief Medical Officer of Esperion Therapeutics, sold 3,285 shares of common stock on June 18, 2024, to satisfy tax obligations related to vested restricted stock units.

Chief Commercial Officer of Esperion Therapeutics, Eric Warren, sold 2,540 shares of common stock on June 18, 2024, to satisfy tax obligations related to vested restricted stock units.

Director J. Martin Carroll acquired 23,000 shares of Esperion Therapeutics common stock and options to purchase 32,500 shares on May 23, 2024.

Director Seth H.Z. Fischer acquired 23,000 shares of common stock and options to purchase 32,500 shares of Esperion Therapeutics, Inc. stock.

Director Alan Fuhrman acquired 23,000 shares of Esperion Therapeutics common stock and options to purchase 32,500 shares on May 23, 2024.

Director Antonio Gotto Jr. reports transactions involving Esperion Therapeutics common stock and stock options, including the acquisition of 23,000 shares and 32,500 stock options on May 23, 2024.

Stephen Rocamboli, a director at Esperion Therapeutics, reported the acquisition of stock and option awards, as well as the disposal of common stock, in a recent SEC filing.

Director Jay Shepard reports acquiring 23,000 shares of common stock and 32,500 stock options in Esperion Therapeutics.

Nicole Vitullo, a director at Esperion Therapeutics, acquired stock options for 65,000 shares at an exercise price of $2.25 on May 23, 2024.

Director Tracy M. Woody acquired 65,000 stock options in Esperion Therapeutics, Inc. on May 23, 2024.

Chief Commercial Officer Eric Warren sold 192 shares of Esperion Therapeutics (ESPR) common stock on May 17, 2024, to satisfy tax obligations related to vested restricted stock units.

Chief Commercial Officer Eric Warren of Esperion Therapeutics reports the acquisition of 100,000 shares of common stock and a stock option grant for 150,000 shares.

Joanne M. Foody, Chief Medical Officer of Esperion Therapeutics, reports the acquisition of 150,000 shares of common stock and 200,000 stock options.

Benjamin Looker, General Counsel of Esperion Therapeutics, reports the acquisition of 100,000 shares of common stock and an option to purchase 150,000 shares.

Esperion Therapeutics' CFO, Benjamin Halladay, reports acquiring 170,000 shares of common stock and receiving options to purchase 200,000 shares.

Esperion Therapeutics CEO Sheldon L. Koenig received 454,000 shares of common stock and options to purchase 642,000 shares on March 14, 2024.